Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Metastatic Castration-Resistant Prostate Cancer

In brief

This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2 studies.

Key facts

Study ID

NCT03437941

Run by

Corcept Therapeutics

People needed

39

Starts

2018-02-20

Expected to finish

2023-01-12

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Scottsdale — Scottsdale, Arizona, United States
• Detroit — Detroit, Michigan, United States
• Basking Ridge — Basking Ridge, New Jersey, United States
• New York — New York, New York, United States
• Portland — Portland, Oregon, United States
• Madison — Madison, Wisconsin, United States
• London — London, England, United Kingdom
• Southampton — Southampton, England, United Kingdom
• Sutton — Sutton, Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.